nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—DRD5—eyelid—skin cancer	0.0409	0.292	CbGeAlD
Pramipexole—DRD1—nerve—skin cancer	0.00833	0.0595	CbGeAlD
Pramipexole—HTR2A—hindlimb—skin cancer	0.00534	0.0381	CbGeAlD
Pramipexole—HTR1B—blood vessel—skin cancer	0.0053	0.0379	CbGeAlD
Pramipexole—HTR1D—blood vessel—skin cancer	0.00513	0.0367	CbGeAlD
Pramipexole—DRD2—nerve—skin cancer	0.00492	0.0352	CbGeAlD
Pramipexole—HTR2A—appendage—skin cancer	0.00458	0.0327	CbGeAlD
Pramipexole—HTR2A—nerve—skin cancer	0.00325	0.0232	CbGeAlD
Pramipexole—DRD5—lymphoid tissue—skin cancer	0.00321	0.0229	CbGeAlD
Pramipexole—DRD5—female reproductive system—skin cancer	0.0031	0.0221	CbGeAlD
Pramipexole—HTR2A—endothelium—skin cancer	0.00277	0.0198	CbGeAlD
Pramipexole—DRD3—head—skin cancer	0.00276	0.0197	CbGeAlD
Pramipexole—ADRA2C—nipple—skin cancer	0.00272	0.0194	CbGeAlD
Pramipexole—HTR1D—connective tissue—skin cancer	0.00263	0.0188	CbGeAlD
Pramipexole—DRD5—head—skin cancer	0.00259	0.0185	CbGeAlD
Pramipexole—HTR2A—blood vessel—skin cancer	0.00255	0.0182	CbGeAlD
Pramipexole—HTR2B—skin of body—skin cancer	0.00221	0.0158	CbGeAlD
Pramipexole—ADRA2A—nipple—skin cancer	0.00217	0.0155	CbGeAlD
Pramipexole—DRD1—head—skin cancer	0.00198	0.0141	CbGeAlD
Pramipexole—HTR1B—female reproductive system—skin cancer	0.00192	0.0137	CbGeAlD
Pramipexole—HTR1D—female reproductive system—skin cancer	0.00186	0.0133	CbGeAlD
Pramipexole—HTR2C—female reproductive system—skin cancer	0.00184	0.0131	CbGeAlD
Pramipexole—HTR2A—neck—skin cancer	0.00182	0.013	CbGeAlD
Pramipexole—HTR2B—female reproductive system—skin cancer	0.00173	0.0123	CbGeAlD
Pramipexole—HTR1B—head—skin cancer	0.0016	0.0114	CbGeAlD
Pramipexole—ADRA2C—mammalian vulva—skin cancer	0.00159	0.0113	CbGeAlD
Pramipexole—SLC22A1—head—skin cancer	0.00157	0.0112	CbGeAlD
Pramipexole—HTR1D—head—skin cancer	0.00155	0.0111	CbGeAlD
Pramipexole—ADRA2A—connective tissue—skin cancer	0.00154	0.011	CbGeAlD
Pramipexole—HTR2C—head—skin cancer	0.00154	0.011	CbGeAlD
Pramipexole—HTR2B—head—skin cancer	0.00144	0.0103	CbGeAlD
Pramipexole—HTR2A—connective tissue—skin cancer	0.00131	0.00934	CbGeAlD
Pramipexole—HTR1A—head—skin cancer	0.00129	0.00923	CbGeAlD
Pramipexole—ADRA2A—mammalian vulva—skin cancer	0.00127	0.00904	CbGeAlD
Pramipexole—HTR2A—epithelium—skin cancer	0.00124	0.00887	CbGeAlD
Pramipexole—DRD2—head—skin cancer	0.00117	0.00834	CbGeAlD
Pramipexole—ADRA2C—head—skin cancer	0.00114	0.00811	CbGeAlD
Pramipexole—ADRA2A—female reproductive system—skin cancer	0.00108	0.00775	CbGeAlD
Pramipexole—HTR2B—lymph node—skin cancer	0.00101	0.00721	CbGeAlD
Pramipexole—HTR2A—female reproductive system—skin cancer	0.000922	0.00659	CbGeAlD
Pramipexole—ADRA2A—head—skin cancer	0.000906	0.00647	CbGeAlD
Pramipexole—ADRA2C—lymph node—skin cancer	0.000795	0.00568	CbGeAlD
Pramipexole—HTR2A—head—skin cancer	0.00077	0.0055	CbGeAlD
Pramipexole—ADRA2A—lymph node—skin cancer	0.000634	0.00453	CbGeAlD
Pramipexole—Dehydration—Docetaxel—skin cancer	0.000487	0.000612	CcSEcCtD
Pramipexole—Ill-defined disorder—Dactinomycin—skin cancer	0.000486	0.000612	CcSEcCtD
Pramipexole—Anaemia—Dactinomycin—skin cancer	0.000484	0.000609	CcSEcCtD
Pramipexole—Vomiting—Vemurafenib—skin cancer	0.000481	0.000605	CcSEcCtD
Pramipexole—Alopecia—Temozolomide—skin cancer	0.000481	0.000605	CcSEcCtD
Pramipexole—Dry skin—Docetaxel—skin cancer	0.00048	0.000603	CcSEcCtD
Pramipexole—Chest pain—Bleomycin—skin cancer	0.000478	0.000602	CcSEcCtD
Pramipexole—Myalgia—Bleomycin—skin cancer	0.000478	0.000602	CcSEcCtD
Pramipexole—Abdominal pain upper—Docetaxel—skin cancer	0.000478	0.000601	CcSEcCtD
Pramipexole—Orthostatic hypotension—Docetaxel—skin cancer	0.000478	0.000601	CcSEcCtD
Pramipexole—Rash—Vemurafenib—skin cancer	0.000477	0.0006	CcSEcCtD
Pramipexole—Mental disorder—Temozolomide—skin cancer	0.000477	0.0006	CcSEcCtD
Pramipexole—Dermatitis—Vemurafenib—skin cancer	0.000477	0.0006	CcSEcCtD
Pramipexole—Hypersensitivity—Imiquimod—skin cancer	0.000476	0.000598	CcSEcCtD
Pramipexole—Headache—Vemurafenib—skin cancer	0.000474	0.000596	CcSEcCtD
Pramipexole—Malnutrition—Temozolomide—skin cancer	0.000474	0.000596	CcSEcCtD
Pramipexole—Erythema—Temozolomide—skin cancer	0.000474	0.000596	CcSEcCtD
Pramipexole—Breast disorder—Docetaxel—skin cancer	0.000473	0.000595	CcSEcCtD
Pramipexole—Discomfort—Bleomycin—skin cancer	0.000473	0.000594	CcSEcCtD
Pramipexole—Malaise—Dactinomycin—skin cancer	0.000473	0.000594	CcSEcCtD
Pramipexole—Cramp muscle—Docetaxel—skin cancer	0.000471	0.000593	CcSEcCtD
Pramipexole—Leukopenia—Dactinomycin—skin cancer	0.000469	0.00059	CcSEcCtD
Pramipexole—Nasopharyngitis—Docetaxel—skin cancer	0.000468	0.000589	CcSEcCtD
Pramipexole—Dysgeusia—Temozolomide—skin cancer	0.000464	0.000584	CcSEcCtD
Pramipexole—Asthenia—Imiquimod—skin cancer	0.000463	0.000583	CcSEcCtD
Pramipexole—Confusional state—Bleomycin—skin cancer	0.000462	0.000582	CcSEcCtD
Pramipexole—Oedema—Bleomycin—skin cancer	0.000459	0.000577	CcSEcCtD
Pramipexole—Back pain—Temozolomide—skin cancer	0.000459	0.000577	CcSEcCtD
Pramipexole—Pruritus—Imiquimod—skin cancer	0.000457	0.000574	CcSEcCtD
Pramipexole—Infection—Bleomycin—skin cancer	0.000456	0.000573	CcSEcCtD
Pramipexole—Dysphagia—Docetaxel—skin cancer	0.000452	0.000569	CcSEcCtD
Pramipexole—Nausea—Vemurafenib—skin cancer	0.00045	0.000566	CcSEcCtD
Pramipexole—Thrombocytopenia—Bleomycin—skin cancer	0.000449	0.000565	CcSEcCtD
Pramipexole—Vision blurred—Temozolomide—skin cancer	0.000447	0.000562	CcSEcCtD
Pramipexole—Myalgia—Dactinomycin—skin cancer	0.000446	0.000561	CcSEcCtD
Pramipexole—Tremor—Temozolomide—skin cancer	0.000444	0.000559	CcSEcCtD
Pramipexole—Alopecia—Fluorouracil—skin cancer	0.000443	0.000558	CcSEcCtD
Pramipexole—Diarrhoea—Imiquimod—skin cancer	0.000442	0.000556	CcSEcCtD
Pramipexole—Discomfort—Dactinomycin—skin cancer	0.000441	0.000554	CcSEcCtD
Pramipexole—Angina pectoris—Docetaxel—skin cancer	0.000441	0.000554	CcSEcCtD
Pramipexole—Ill-defined disorder—Temozolomide—skin cancer	0.00044	0.000553	CcSEcCtD
Pramipexole—Anaemia—Temozolomide—skin cancer	0.000438	0.000551	CcSEcCtD
Pramipexole—Anorexia—Bleomycin—skin cancer	0.000437	0.00055	CcSEcCtD
Pramipexole—Erythema—Fluorouracil—skin cancer	0.000437	0.000549	CcSEcCtD
Pramipexole—Agitation—Temozolomide—skin cancer	0.000436	0.000548	CcSEcCtD
Pramipexole—Hypotension—Bleomycin—skin cancer	0.000429	0.000539	CcSEcCtD
Pramipexole—Oedema—Dactinomycin—skin cancer	0.000428	0.000538	CcSEcCtD
Pramipexole—Malaise—Temozolomide—skin cancer	0.000428	0.000538	CcSEcCtD
Pramipexole—Dizziness—Imiquimod—skin cancer	0.000427	0.000537	CcSEcCtD
Pramipexole—Vertigo—Temozolomide—skin cancer	0.000426	0.000536	CcSEcCtD
Pramipexole—Infection—Dactinomycin—skin cancer	0.000425	0.000534	CcSEcCtD
Pramipexole—Leukopenia—Temozolomide—skin cancer	0.000424	0.000534	CcSEcCtD
Pramipexole—Palpitations—Temozolomide—skin cancer	0.000419	0.000527	CcSEcCtD
Pramipexole—Thrombocytopenia—Dactinomycin—skin cancer	0.000419	0.000527	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000418	0.000526	CcSEcCtD
Pramipexole—Cough—Temozolomide—skin cancer	0.000414	0.00052	CcSEcCtD
Pramipexole—Paraesthesia—Bleomycin—skin cancer	0.000412	0.000518	CcSEcCtD
Pramipexole—Weight increased—Docetaxel—skin cancer	0.000412	0.000518	CcSEcCtD
Pramipexole—Vision blurred—Fluorouracil—skin cancer	0.000412	0.000518	CcSEcCtD
Pramipexole—Convulsion—Temozolomide—skin cancer	0.000411	0.000517	CcSEcCtD
Pramipexole—Vomiting—Imiquimod—skin cancer	0.000411	0.000516	CcSEcCtD
Pramipexole—Weight decreased—Docetaxel—skin cancer	0.000409	0.000515	CcSEcCtD
Pramipexole—Hypertension—Temozolomide—skin cancer	0.000409	0.000515	CcSEcCtD
Pramipexole—Dyspnoea—Bleomycin—skin cancer	0.000409	0.000514	CcSEcCtD
Pramipexole—Anorexia—Dactinomycin—skin cancer	0.000408	0.000513	CcSEcCtD
Pramipexole—Rash—Imiquimod—skin cancer	0.000407	0.000512	CcSEcCtD
Pramipexole—Dermatitis—Imiquimod—skin cancer	0.000407	0.000511	CcSEcCtD
Pramipexole—Pneumonia—Docetaxel—skin cancer	0.000406	0.00051	CcSEcCtD
Pramipexole—Headache—Imiquimod—skin cancer	0.000404	0.000509	CcSEcCtD
Pramipexole—Anaemia—Fluorouracil—skin cancer	0.000404	0.000508	CcSEcCtD
Pramipexole—Arthralgia—Temozolomide—skin cancer	0.000404	0.000508	CcSEcCtD
Pramipexole—Myalgia—Temozolomide—skin cancer	0.000404	0.000508	CcSEcCtD
Pramipexole—Infestation—Docetaxel—skin cancer	0.000403	0.000507	CcSEcCtD
Pramipexole—Infestation NOS—Docetaxel—skin cancer	0.000403	0.000507	CcSEcCtD
Pramipexole—Anxiety—Temozolomide—skin cancer	0.000402	0.000506	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000401	0.000504	CcSEcCtD
Pramipexole—Discomfort—Temozolomide—skin cancer	0.000399	0.000501	CcSEcCtD
Pramipexole—Decreased appetite—Bleomycin—skin cancer	0.000399	0.000501	CcSEcCtD
Pramipexole—Acute coronary syndrome—Docetaxel—skin cancer	0.000398	0.0005	CcSEcCtD
Pramipexole—Renal failure—Docetaxel—skin cancer	0.000397	0.000499	CcSEcCtD
Pramipexole—Myocardial infarction—Docetaxel—skin cancer	0.000395	0.000497	CcSEcCtD
Pramipexole—Neuropathy peripheral—Docetaxel—skin cancer	0.000395	0.000497	CcSEcCtD
Pramipexole—Dry mouth—Temozolomide—skin cancer	0.000395	0.000496	CcSEcCtD
Pramipexole—Pain—Bleomycin—skin cancer	0.000392	0.000493	CcSEcCtD
Pramipexole—Conjunctivitis—Docetaxel—skin cancer	0.000392	0.000493	CcSEcCtD
Pramipexole—Leukopenia—Fluorouracil—skin cancer	0.000391	0.000492	CcSEcCtD
Pramipexole—Confusional state—Temozolomide—skin cancer	0.00039	0.000491	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00039	0.00049	CcSEcCtD
Pramipexole—Oedema—Temozolomide—skin cancer	0.000387	0.000487	CcSEcCtD
Pramipexole—Infection—Temozolomide—skin cancer	0.000384	0.000483	CcSEcCtD
Pramipexole—Nausea—Imiquimod—skin cancer	0.000383	0.000482	CcSEcCtD
Pramipexole—Hepatobiliary disease—Docetaxel—skin cancer	0.000382	0.00048	CcSEcCtD
Pramipexole—Epistaxis—Docetaxel—skin cancer	0.000381	0.000479	CcSEcCtD
Pramipexole—Nervous system disorder—Temozolomide—skin cancer	0.000379	0.000477	CcSEcCtD
Pramipexole—Thrombocytopenia—Temozolomide—skin cancer	0.000379	0.000476	CcSEcCtD
Pramipexole—Convulsion—Fluorouracil—skin cancer	0.000378	0.000476	CcSEcCtD
Pramipexole—Feeling abnormal—Bleomycin—skin cancer	0.000378	0.000475	CcSEcCtD
Pramipexole—Skin disorder—Temozolomide—skin cancer	0.000376	0.000473	CcSEcCtD
Pramipexole—Hyperhidrosis—Temozolomide—skin cancer	0.000374	0.00047	CcSEcCtD
Pramipexole—Chest pain—Fluorouracil—skin cancer	0.000372	0.000468	CcSEcCtD
Pramipexole—Myalgia—Fluorouracil—skin cancer	0.000372	0.000468	CcSEcCtD
Pramipexole—Decreased appetite—Dactinomycin—skin cancer	0.000372	0.000468	CcSEcCtD
Pramipexole—Fatigue—Dactinomycin—skin cancer	0.000369	0.000464	CcSEcCtD
Pramipexole—Anorexia—Temozolomide—skin cancer	0.000369	0.000464	CcSEcCtD
Pramipexole—Discomfort—Fluorouracil—skin cancer	0.000367	0.000462	CcSEcCtD
Pramipexole—Pain—Dactinomycin—skin cancer	0.000366	0.00046	CcSEcCtD
Pramipexole—Urticaria—Bleomycin—skin cancer	0.000364	0.000458	CcSEcCtD
Pramipexole—Rhinitis—Docetaxel—skin cancer	0.000363	0.000457	CcSEcCtD
Pramipexole—Body temperature increased—Bleomycin—skin cancer	0.000363	0.000456	CcSEcCtD
Pramipexole—Hypoaesthesia—Docetaxel—skin cancer	0.00036	0.000453	CcSEcCtD
Pramipexole—Confusional state—Fluorouracil—skin cancer	0.000359	0.000452	CcSEcCtD
Pramipexole—Pharyngitis—Docetaxel—skin cancer	0.000359	0.000452	CcSEcCtD
Pramipexole—Urinary tract disorder—Docetaxel—skin cancer	0.000358	0.00045	CcSEcCtD
Pramipexole—Oedema peripheral—Docetaxel—skin cancer	0.000357	0.000449	CcSEcCtD
Pramipexole—Oedema—Fluorouracil—skin cancer	0.000356	0.000448	CcSEcCtD
Pramipexole—Connective tissue disorder—Docetaxel—skin cancer	0.000356	0.000448	CcSEcCtD
Pramipexole—Urethral disorder—Docetaxel—skin cancer	0.000355	0.000446	CcSEcCtD
Pramipexole—Infection—Fluorouracil—skin cancer	0.000354	0.000445	CcSEcCtD
Pramipexole—Feeling abnormal—Dactinomycin—skin cancer	0.000353	0.000443	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000353	0.000443	CcSEcCtD
Pramipexole—Insomnia—Temozolomide—skin cancer	0.00035	0.00044	CcSEcCtD
Pramipexole—Gastrointestinal pain—Dactinomycin—skin cancer	0.00035	0.00044	CcSEcCtD
Pramipexole—Nervous system disorder—Fluorouracil—skin cancer	0.00035	0.00044	CcSEcCtD
Pramipexole—Thrombocytopenia—Fluorouracil—skin cancer	0.000349	0.000439	CcSEcCtD
Pramipexole—Visual impairment—Docetaxel—skin cancer	0.000349	0.000439	CcSEcCtD
Pramipexole—Tachycardia—Fluorouracil—skin cancer	0.000348	0.000438	CcSEcCtD
Pramipexole—Paraesthesia—Temozolomide—skin cancer	0.000347	0.000437	CcSEcCtD
Pramipexole—Dyspnoea—Temozolomide—skin cancer	0.000345	0.000434	CcSEcCtD
Pramipexole—Somnolence—Temozolomide—skin cancer	0.000344	0.000433	CcSEcCtD
Pramipexole—Dyspepsia—Temozolomide—skin cancer	0.000341	0.000428	CcSEcCtD
Pramipexole—Anorexia—Fluorouracil—skin cancer	0.00034	0.000427	CcSEcCtD
Pramipexole—Eye disorder—Docetaxel—skin cancer	0.000338	0.000426	CcSEcCtD
Pramipexole—Body temperature increased—Dactinomycin—skin cancer	0.000338	0.000425	CcSEcCtD
Pramipexole—Abdominal pain—Dactinomycin—skin cancer	0.000338	0.000425	CcSEcCtD
Pramipexole—Hypersensitivity—Bleomycin—skin cancer	0.000338	0.000425	CcSEcCtD
Pramipexole—Decreased appetite—Temozolomide—skin cancer	0.000336	0.000423	CcSEcCtD
Pramipexole—Cardiac disorder—Docetaxel—skin cancer	0.000336	0.000423	CcSEcCtD
Pramipexole—Flushing—Docetaxel—skin cancer	0.000336	0.000423	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Temozolomide—skin cancer	0.000334	0.00042	CcSEcCtD
Pramipexole—Fatigue—Temozolomide—skin cancer	0.000334	0.000419	CcSEcCtD
Pramipexole—Hypotension—Fluorouracil—skin cancer	0.000333	0.000419	CcSEcCtD
Pramipexole—Pain—Temozolomide—skin cancer	0.000331	0.000416	CcSEcCtD
Pramipexole—Constipation—Temozolomide—skin cancer	0.000331	0.000416	CcSEcCtD
Pramipexole—Asthenia—Bleomycin—skin cancer	0.000329	0.000414	CcSEcCtD
Pramipexole—Angiopathy—Docetaxel—skin cancer	0.000329	0.000413	CcSEcCtD
Pramipexole—Immune system disorder—Docetaxel—skin cancer	0.000327	0.000411	CcSEcCtD
Pramipexole—Mediastinal disorder—Docetaxel—skin cancer	0.000326	0.00041	CcSEcCtD
Pramipexole—Chills—Docetaxel—skin cancer	0.000325	0.000409	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000325	0.000408	CcSEcCtD
Pramipexole—Pruritus—Bleomycin—skin cancer	0.000325	0.000408	CcSEcCtD
Pramipexole—Insomnia—Fluorouracil—skin cancer	0.000322	0.000405	CcSEcCtD
Pramipexole—Paraesthesia—Fluorouracil—skin cancer	0.00032	0.000403	CcSEcCtD
Pramipexole—Alopecia—Docetaxel—skin cancer	0.00032	0.000402	CcSEcCtD
Pramipexole—Feeling abnormal—Temozolomide—skin cancer	0.000319	0.000401	CcSEcCtD
Pramipexole—Dyspnoea—Fluorouracil—skin cancer	0.000318	0.0004	CcSEcCtD
Pramipexole—Mental disorder—Docetaxel—skin cancer	0.000317	0.000399	CcSEcCtD
Pramipexole—Somnolence—Fluorouracil—skin cancer	0.000317	0.000399	CcSEcCtD
Pramipexole—Gastrointestinal pain—Temozolomide—skin cancer	0.000316	0.000398	CcSEcCtD
Pramipexole—Erythema—Docetaxel—skin cancer	0.000315	0.000396	CcSEcCtD
Pramipexole—Malnutrition—Docetaxel—skin cancer	0.000315	0.000396	CcSEcCtD
Pramipexole—Hypersensitivity—Dactinomycin—skin cancer	0.000315	0.000396	CcSEcCtD
Pramipexole—Dyspepsia—Fluorouracil—skin cancer	0.000314	0.000395	CcSEcCtD
Pramipexole—Decreased appetite—Fluorouracil—skin cancer	0.00031	0.00039	CcSEcCtD
Pramipexole—Dysgeusia—Docetaxel—skin cancer	0.000309	0.000388	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000308	0.000387	CcSEcCtD
Pramipexole—Urticaria—Temozolomide—skin cancer	0.000307	0.000387	CcSEcCtD
Pramipexole—Asthenia—Dactinomycin—skin cancer	0.000307	0.000386	CcSEcCtD
Pramipexole—Abdominal pain—Temozolomide—skin cancer	0.000306	0.000385	CcSEcCtD
Pramipexole—Body temperature increased—Temozolomide—skin cancer	0.000306	0.000385	CcSEcCtD
Pramipexole—Back pain—Docetaxel—skin cancer	0.000305	0.000383	CcSEcCtD
Pramipexole—Pain—Fluorouracil—skin cancer	0.000305	0.000383	CcSEcCtD
Pramipexole—Muscle spasms—Docetaxel—skin cancer	0.000303	0.000381	CcSEcCtD
Pramipexole—Feeling abnormal—Fluorouracil—skin cancer	0.000294	0.000369	CcSEcCtD
Pramipexole—Diarrhoea—Dactinomycin—skin cancer	0.000293	0.000368	CcSEcCtD
Pramipexole—Vomiting—Bleomycin—skin cancer	0.000292	0.000367	CcSEcCtD
Pramipexole—Anaemia—Docetaxel—skin cancer	0.000291	0.000366	CcSEcCtD
Pramipexole—Rash—Bleomycin—skin cancer	0.000289	0.000364	CcSEcCtD
Pramipexole—Dermatitis—Bleomycin—skin cancer	0.000289	0.000363	CcSEcCtD
Pramipexole—Hypersensitivity—Temozolomide—skin cancer	0.000285	0.000358	CcSEcCtD
Pramipexole—Urticaria—Fluorouracil—skin cancer	0.000283	0.000356	CcSEcCtD
Pramipexole—Syncope—Docetaxel—skin cancer	0.000283	0.000356	CcSEcCtD
Pramipexole—Leukopenia—Docetaxel—skin cancer	0.000282	0.000355	CcSEcCtD
Pramipexole—Body temperature increased—Fluorouracil—skin cancer	0.000282	0.000354	CcSEcCtD
Pramipexole—Palpitations—Docetaxel—skin cancer	0.000279	0.00035	CcSEcCtD
Pramipexole—Asthenia—Temozolomide—skin cancer	0.000278	0.000349	CcSEcCtD
Pramipexole—Loss of consciousness—Docetaxel—skin cancer	0.000277	0.000348	CcSEcCtD
Pramipexole—Cough—Docetaxel—skin cancer	0.000275	0.000346	CcSEcCtD
Pramipexole—Pruritus—Temozolomide—skin cancer	0.000274	0.000344	CcSEcCtD
Pramipexole—Convulsion—Docetaxel—skin cancer	0.000273	0.000344	CcSEcCtD
Pramipexole—Nausea—Bleomycin—skin cancer	0.000272	0.000343	CcSEcCtD
Pramipexole—Hypertension—Docetaxel—skin cancer	0.000272	0.000342	CcSEcCtD
Pramipexole—Vomiting—Dactinomycin—skin cancer	0.000272	0.000342	CcSEcCtD
Pramipexole—Rash—Dactinomycin—skin cancer	0.00027	0.000339	CcSEcCtD
Pramipexole—Arthralgia—Docetaxel—skin cancer	0.000268	0.000338	CcSEcCtD
Pramipexole—Chest pain—Docetaxel—skin cancer	0.000268	0.000338	CcSEcCtD
Pramipexole—Myalgia—Docetaxel—skin cancer	0.000268	0.000338	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000267	0.000335	CcSEcCtD
Pramipexole—Diarrhoea—Temozolomide—skin cancer	0.000265	0.000333	CcSEcCtD
Pramipexole—Hypersensitivity—Fluorouracil—skin cancer	0.000263	0.00033	CcSEcCtD
Pramipexole—Dry mouth—Docetaxel—skin cancer	0.000262	0.00033	CcSEcCtD
Pramipexole—Confusional state—Docetaxel—skin cancer	0.000259	0.000326	CcSEcCtD
Pramipexole—Oedema—Docetaxel—skin cancer	0.000257	0.000324	CcSEcCtD
Pramipexole—Dizziness—Temozolomide—skin cancer	0.000256	0.000322	CcSEcCtD
Pramipexole—Infection—Docetaxel—skin cancer	0.000256	0.000321	CcSEcCtD
Pramipexole—Nausea—Dactinomycin—skin cancer	0.000254	0.00032	CcSEcCtD
Pramipexole—Shock—Docetaxel—skin cancer	0.000253	0.000318	CcSEcCtD
Pramipexole—Nervous system disorder—Docetaxel—skin cancer	0.000252	0.000317	CcSEcCtD
Pramipexole—Pruritus—Fluorouracil—skin cancer	0.000252	0.000317	CcSEcCtD
Pramipexole—Thrombocytopenia—Docetaxel—skin cancer	0.000252	0.000317	CcSEcCtD
Pramipexole—Tachycardia—Docetaxel—skin cancer	0.000251	0.000316	CcSEcCtD
Pramipexole—Skin disorder—Docetaxel—skin cancer	0.00025	0.000314	CcSEcCtD
Pramipexole—Vomiting—Temozolomide—skin cancer	0.000246	0.000309	CcSEcCtD
Pramipexole—Anorexia—Docetaxel—skin cancer	0.000245	0.000308	CcSEcCtD
Pramipexole—Rash—Temozolomide—skin cancer	0.000244	0.000307	CcSEcCtD
Pramipexole—Diarrhoea—Fluorouracil—skin cancer	0.000244	0.000307	CcSEcCtD
Pramipexole—Dermatitis—Temozolomide—skin cancer	0.000244	0.000307	CcSEcCtD
Pramipexole—Headache—Temozolomide—skin cancer	0.000242	0.000305	CcSEcCtD
Pramipexole—Hypotension—Docetaxel—skin cancer	0.00024	0.000302	CcSEcCtD
Pramipexole—Dizziness—Fluorouracil—skin cancer	0.000236	0.000296	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000234	0.000295	CcSEcCtD
Pramipexole—Insomnia—Docetaxel—skin cancer	0.000233	0.000293	CcSEcCtD
Pramipexole—Paraesthesia—Docetaxel—skin cancer	0.000231	0.000291	CcSEcCtD
Pramipexole—Nausea—Temozolomide—skin cancer	0.00023	0.000289	CcSEcCtD
Pramipexole—Dyspnoea—Docetaxel—skin cancer	0.000229	0.000288	CcSEcCtD
Pramipexole—Somnolence—Docetaxel—skin cancer	0.000229	0.000288	CcSEcCtD
Pramipexole—Vomiting—Fluorouracil—skin cancer	0.000227	0.000285	CcSEcCtD
Pramipexole—Dyspepsia—Docetaxel—skin cancer	0.000226	0.000285	CcSEcCtD
Pramipexole—Rash—Fluorouracil—skin cancer	0.000225	0.000283	CcSEcCtD
Pramipexole—Dermatitis—Fluorouracil—skin cancer	0.000225	0.000282	CcSEcCtD
Pramipexole—Decreased appetite—Docetaxel—skin cancer	0.000224	0.000281	CcSEcCtD
Pramipexole—Headache—Fluorouracil—skin cancer	0.000223	0.000281	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Docetaxel—skin cancer	0.000222	0.000279	CcSEcCtD
Pramipexole—Fatigue—Docetaxel—skin cancer	0.000222	0.000279	CcSEcCtD
Pramipexole—Pain—Docetaxel—skin cancer	0.00022	0.000277	CcSEcCtD
Pramipexole—Constipation—Docetaxel—skin cancer	0.00022	0.000277	CcSEcCtD
Pramipexole—Feeling abnormal—Docetaxel—skin cancer	0.000212	0.000267	CcSEcCtD
Pramipexole—Nausea—Fluorouracil—skin cancer	0.000212	0.000266	CcSEcCtD
Pramipexole—Gastrointestinal pain—Docetaxel—skin cancer	0.00021	0.000265	CcSEcCtD
Pramipexole—Body temperature increased—Docetaxel—skin cancer	0.000203	0.000256	CcSEcCtD
Pramipexole—Abdominal pain—Docetaxel—skin cancer	0.000203	0.000256	CcSEcCtD
Pramipexole—Hypersensitivity—Docetaxel—skin cancer	0.00019	0.000238	CcSEcCtD
Pramipexole—Asthenia—Docetaxel—skin cancer	0.000185	0.000232	CcSEcCtD
Pramipexole—Pruritus—Docetaxel—skin cancer	0.000182	0.000229	CcSEcCtD
Pramipexole—Diarrhoea—Docetaxel—skin cancer	0.000176	0.000221	CcSEcCtD
Pramipexole—Dizziness—Docetaxel—skin cancer	0.00017	0.000214	CcSEcCtD
Pramipexole—Vomiting—Docetaxel—skin cancer	0.000164	0.000206	CcSEcCtD
Pramipexole—Rash—Docetaxel—skin cancer	0.000162	0.000204	CcSEcCtD
Pramipexole—Dermatitis—Docetaxel—skin cancer	0.000162	0.000204	CcSEcCtD
Pramipexole—Headache—Docetaxel—skin cancer	0.000161	0.000203	CcSEcCtD
Pramipexole—Nausea—Docetaxel—skin cancer	0.000153	0.000192	CcSEcCtD
Pramipexole—ADRA2C—Metabolism—ENO2—skin cancer	4.56e-05	0.000703	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—GLI2—skin cancer	4.55e-05	0.000703	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—RASA1—skin cancer	4.55e-05	0.000702	CbGpPWpGaD
Pramipexole—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	4.54e-05	0.000701	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—SUFU—skin cancer	4.53e-05	0.000699	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—SHH—skin cancer	4.52e-05	0.000697	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—RASA1—skin cancer	4.49e-05	0.000693	CbGpPWpGaD
Pramipexole—SLC22A1—Transmission across Chemical Synapses—HRAS—skin cancer	4.49e-05	0.000692	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—PTGER4—skin cancer	4.48e-05	0.000691	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SUFU—skin cancer	4.46e-05	0.000688	CbGpPWpGaD
Pramipexole—DRD2—Circadian rythm related genes—TP53—skin cancer	4.42e-05	0.000683	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—ENO2—skin cancer	4.37e-05	0.000674	CbGpPWpGaD
Pramipexole—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	4.35e-05	0.000671	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MC1R—skin cancer	4.34e-05	0.00067	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—SMO—skin cancer	4.34e-05	0.00067	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—PTCH1—skin cancer	4.34e-05	0.00067	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—FOXO4—skin cancer	4.3e-05	0.000664	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—PTCH1—skin cancer	4.28e-05	0.000661	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—SMO—skin cancer	4.28e-05	0.000661	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—GLI1—skin cancer	4.28e-05	0.000661	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—PTGER4—skin cancer	4.22e-05	0.000652	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—FOXO4—skin cancer	4.21e-05	0.00065	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—PTGER4—skin cancer	4.17e-05	0.000643	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—FOXO4—skin cancer	4.15e-05	0.00064	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—SHH—skin cancer	4.08e-05	0.000629	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SUFU—skin cancer	4.06e-05	0.000626	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—RASA1—skin cancer	4.05e-05	0.000625	CbGpPWpGaD
Pramipexole—DRD2—Circadian rythm related genes—IL6—skin cancer	4.05e-05	0.000625	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—FOXO4—skin cancer	3.96e-05	0.000611	CbGpPWpGaD
Pramipexole—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	3.94e-05	0.000609	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—SHH—skin cancer	3.94e-05	0.000608	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—SHH—skin cancer	3.92e-05	0.000604	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—RASA1—skin cancer	3.91e-05	0.000604	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—RASA1—skin cancer	3.89e-05	0.000601	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PTCH1—skin cancer	3.87e-05	0.000597	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—SMO—skin cancer	3.87e-05	0.000597	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—SHH—skin cancer	3.81e-05	0.000588	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—RASA1—skin cancer	3.79e-05	0.000584	CbGpPWpGaD
Pramipexole—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	3.77e-05	0.000583	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PTGER4—skin cancer	3.76e-05	0.000581	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—TERT—skin cancer	3.75e-05	0.000579	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—FOXO4—skin cancer	3.73e-05	0.000576	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PTCH1—skin cancer	3.73e-05	0.000576	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—SMO—skin cancer	3.73e-05	0.000576	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PTCH1—skin cancer	3.71e-05	0.000573	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—SMO—skin cancer	3.71e-05	0.000573	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—ENO2—skin cancer	3.7e-05	0.000571	CbGpPWpGaD
Pramipexole—SLC22A2—Neuronal System—HRAS—skin cancer	3.69e-05	0.000569	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—FOXO4—skin cancer	3.68e-05	0.000568	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PTGER4—skin cancer	3.63e-05	0.000561	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PTGER4—skin cancer	3.61e-05	0.000558	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PTCH1—skin cancer	3.61e-05	0.000557	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—SMO—skin cancer	3.61e-05	0.000557	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PTGER4—skin cancer	3.52e-05	0.000543	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—SHH—skin cancer	3.46e-05	0.000533	CbGpPWpGaD
Pramipexole—SLC22A1—Neuronal System—HRAS—skin cancer	3.44e-05	0.00053	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—RASA1—skin cancer	3.43e-05	0.00053	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SHH—skin cancer	3.4e-05	0.000525	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—RASA1—skin cancer	3.38e-05	0.000522	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—FOXO4—skin cancer	3.32e-05	0.000513	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—SMO—skin cancer	3.28e-05	0.000506	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PTCH1—skin cancer	3.28e-05	0.000506	CbGpPWpGaD
Pramipexole—ADRA2B—Hemostasis—NRAS—skin cancer	3.26e-05	0.000503	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PTCH1—skin cancer	3.22e-05	0.000498	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SMO—skin cancer	3.22e-05	0.000498	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—FOXO4—skin cancer	3.21e-05	0.000495	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—FOXO4—skin cancer	3.19e-05	0.000493	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PTGER4—skin cancer	3.19e-05	0.000492	CbGpPWpGaD
Pramipexole—DRD5—Signaling by GPCR—NRAS—skin cancer	3.16e-05	0.000488	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PTGER4—skin cancer	3.14e-05	0.000484	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—FOXO4—skin cancer	3.11e-05	0.000479	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SHH—skin cancer	3.09e-05	0.000478	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—RASA1—skin cancer	3.07e-05	0.000475	CbGpPWpGaD
Pramipexole—ADRA2C—Hemostasis—NRAS—skin cancer	3.04e-05	0.00047	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—BRAF—skin cancer	2.97e-05	0.000459	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SMO—skin cancer	2.93e-05	0.000453	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PTCH1—skin cancer	2.93e-05	0.000453	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TERT—skin cancer	2.87e-05	0.000444	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PTGER4—skin cancer	2.86e-05	0.000441	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—FOXO4—skin cancer	2.82e-05	0.000435	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TERT—skin cancer	2.81e-05	0.000434	CbGpPWpGaD
Pramipexole—ADRA2B—Hemostasis—KRAS—skin cancer	2.81e-05	0.000433	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—FOXO4—skin cancer	2.77e-05	0.000428	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TERT—skin cancer	2.77e-05	0.000427	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—ERCC2—skin cancer	2.72e-05	0.00042	CbGpPWpGaD
Pramipexole—DRD5—Signaling by GPCR—KRAS—skin cancer	2.72e-05	0.00042	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—ERCC2—skin cancer	2.65e-05	0.000408	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TERT—skin cancer	2.64e-05	0.000408	CbGpPWpGaD
Pramipexole—ADRA2C—Hemostasis—KRAS—skin cancer	2.62e-05	0.000404	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—ERCC2—skin cancer	2.54e-05	0.000391	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—FOXO4—skin cancer	2.52e-05	0.000389	CbGpPWpGaD
Pramipexole—ADRA2B—Hemostasis—TP53—skin cancer	2.49e-05	0.000385	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TERT—skin cancer	2.49e-05	0.000385	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—NRAS—skin cancer	2.47e-05	0.000382	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TERT—skin cancer	2.46e-05	0.00038	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—NRAS—skin cancer	2.42e-05	0.000374	CbGpPWpGaD
Pramipexole—ADRA2B—Hemostasis—HRAS—skin cancer	2.38e-05	0.000368	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—NRAS—skin cancer	2.37e-05	0.000366	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—NRAS—skin cancer	2.33e-05	0.00036	CbGpPWpGaD
Pramipexole—ADRA2C—Hemostasis—TP53—skin cancer	2.33e-05	0.000359	CbGpPWpGaD
Pramipexole—DRD5—Signaling by GPCR—HRAS—skin cancer	2.31e-05	0.000357	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—BRAF—skin cancer	2.28e-05	0.000351	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—BRAF—skin cancer	2.23e-05	0.000344	CbGpPWpGaD
Pramipexole—ADRA2C—Hemostasis—HRAS—skin cancer	2.23e-05	0.000344	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—NRAS—skin cancer	2.23e-05	0.000344	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TERT—skin cancer	2.22e-05	0.000343	CbGpPWpGaD
Pramipexole—DRD5—Signaling by GPCR—IL6—skin cancer	2.21e-05	0.000342	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—BRAF—skin cancer	2.19e-05	0.000338	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—ERCC2—skin cancer	2.15e-05	0.000332	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TERT—skin cancer	2.14e-05	0.000331	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TERT—skin cancer	2.13e-05	0.000329	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—KRAS—skin cancer	2.13e-05	0.000329	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—NRAS—skin cancer	2.1e-05	0.000324	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—BRAF—skin cancer	2.09e-05	0.000323	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—KRAS—skin cancer	2.08e-05	0.000322	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TERT—skin cancer	2.07e-05	0.00032	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—NRAS—skin cancer	2.07e-05	0.00032	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—KRAS—skin cancer	2.04e-05	0.000315	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—KRAS—skin cancer	2.01e-05	0.00031	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—BRAF—skin cancer	1.97e-05	0.000305	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—BRAF—skin cancer	1.95e-05	0.000301	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—KRAS—skin cancer	1.92e-05	0.000296	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—TP53—skin cancer	1.89e-05	0.000292	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TERT—skin cancer	1.88e-05	0.00029	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—NRAS—skin cancer	1.87e-05	0.000289	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—NRAS—skin cancer	1.87e-05	0.000288	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TERT—skin cancer	1.85e-05	0.000286	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—HRAS—skin cancer	1.81e-05	0.000279	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—KRAS—skin cancer	1.81e-05	0.000279	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—NRAS—skin cancer	1.81e-05	0.000279	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—NRAS—skin cancer	1.8e-05	0.000277	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—KRAS—skin cancer	1.78e-05	0.000275	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—HRAS—skin cancer	1.77e-05	0.000273	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—BRAF—skin cancer	1.76e-05	0.000271	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—NRAS—skin cancer	1.75e-05	0.00027	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—HRAS—skin cancer	1.73e-05	0.000268	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—HRAS—skin cancer	1.71e-05	0.000263	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—BRAF—skin cancer	1.7e-05	0.000262	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—IL6—skin cancer	1.7e-05	0.000262	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—BRAF—skin cancer	1.69e-05	0.000261	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TERT—skin cancer	1.68e-05	0.00026	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—IL6—skin cancer	1.66e-05	0.000256	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—BRAF—skin cancer	1.64e-05	0.000254	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—IL6—skin cancer	1.63e-05	0.000252	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PTGS2—skin cancer	1.63e-05	0.000252	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—HRAS—skin cancer	1.63e-05	0.000251	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—KRAS—skin cancer	1.61e-05	0.000249	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—KRAS—skin cancer	1.61e-05	0.000248	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PTGS2—skin cancer	1.59e-05	0.000245	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—NRAS—skin cancer	1.59e-05	0.000245	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—NRAS—skin cancer	1.56e-05	0.000241	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—IL6—skin cancer	1.56e-05	0.000241	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—KRAS—skin cancer	1.55e-05	0.00024	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—KRAS—skin cancer	1.55e-05	0.000239	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—HRAS—skin cancer	1.54e-05	0.000237	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PTGS2—skin cancer	1.52e-05	0.000235	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—HRAS—skin cancer	1.52e-05	0.000234	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—KRAS—skin cancer	1.5e-05	0.000232	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—BRAF—skin cancer	1.49e-05	0.00023	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—IL6—skin cancer	1.47e-05	0.000227	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—BRAF—skin cancer	1.47e-05	0.000226	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—IL6—skin cancer	1.45e-05	0.000224	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—NRAS—skin cancer	1.43e-05	0.000221	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—TP53—skin cancer	1.43e-05	0.00022	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—NRAS—skin cancer	1.42e-05	0.000219	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—NRAS—skin cancer	1.4e-05	0.000216	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—NRAS—skin cancer	1.38e-05	0.000213	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—HRAS—skin cancer	1.37e-05	0.000211	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—HRAS—skin cancer	1.37e-05	0.000211	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—KRAS—skin cancer	1.36e-05	0.000211	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—KRAS—skin cancer	1.34e-05	0.000207	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—BRAF—skin cancer	1.33e-05	0.000206	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—HRAS—skin cancer	1.32e-05	0.000204	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—NRAS—skin cancer	1.32e-05	0.000203	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—HRAS—skin cancer	1.31e-05	0.000203	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—IL6—skin cancer	1.31e-05	0.000202	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—IL6—skin cancer	1.31e-05	0.000202	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTGS2—skin cancer	1.29e-05	0.000199	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—HRAS—skin cancer	1.28e-05	0.000197	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL6—skin cancer	1.26e-05	0.000195	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL6—skin cancer	1.26e-05	0.000194	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—NRAS—skin cancer	1.24e-05	0.000191	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—KRAS—skin cancer	1.23e-05	0.00019	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—NRAS—skin cancer	1.22e-05	0.000189	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL6—skin cancer	1.22e-05	0.000189	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—KRAS—skin cancer	1.22e-05	0.000189	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—KRAS—skin cancer	1.21e-05	0.000186	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—KRAS—skin cancer	1.19e-05	0.000183	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—HRAS—skin cancer	1.16e-05	0.000179	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—HRAS—skin cancer	1.14e-05	0.000176	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—KRAS—skin cancer	1.13e-05	0.000175	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL6—skin cancer	1.11e-05	0.000171	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—NRAS—skin cancer	1.11e-05	0.000171	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TP53—skin cancer	1.09e-05	0.000169	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL6—skin cancer	1.09e-05	0.000169	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TP53—skin cancer	1.07e-05	0.000165	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—KRAS—skin cancer	1.07e-05	0.000165	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—NRAS—skin cancer	1.07e-05	0.000165	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—NRAS—skin cancer	1.06e-05	0.000164	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TP53—skin cancer	1.05e-05	0.000163	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—KRAS—skin cancer	1.05e-05	0.000163	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—HRAS—skin cancer	1.05e-05	0.000161	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—HRAS—skin cancer	1.04e-05	0.00016	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NRAS—skin cancer	1.03e-05	0.000159	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—HRAS—skin cancer	1.02e-05	0.000158	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—HRAS—skin cancer	1.01e-05	0.000156	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TP53—skin cancer	1.01e-05	0.000155	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL6—skin cancer	1e-05	0.000155	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL6—skin cancer	9.94e-06	0.000153	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL6—skin cancer	9.81e-06	0.000151	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL6—skin cancer	9.65e-06	0.000149	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—HRAS—skin cancer	9.62e-06	0.000149	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—KRAS—skin cancer	9.51e-06	0.000147	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TP53—skin cancer	9.49e-06	0.000146	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NRAS—skin cancer	9.37e-06	0.000145	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TP53—skin cancer	9.36e-06	0.000145	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NRAS—skin cancer	9.22e-06	0.000142	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL6—skin cancer	9.21e-06	0.000142	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—KRAS—skin cancer	9.18e-06	0.000142	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—KRAS—skin cancer	9.13e-06	0.000141	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—HRAS—skin cancer	9.08e-06	0.00014	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—HRAS—skin cancer	8.95e-06	0.000138	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—KRAS—skin cancer	8.88e-06	0.000137	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL6—skin cancer	8.69e-06	0.000134	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL6—skin cancer	8.57e-06	0.000132	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TP53—skin cancer	8.45e-06	0.00013	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NRAS—skin cancer	8.38e-06	0.000129	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TP53—skin cancer	8.16e-06	0.000126	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TP53—skin cancer	8.12e-06	0.000125	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—HRAS—skin cancer	8.08e-06	0.000125	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—KRAS—skin cancer	8.06e-06	0.000124	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—KRAS—skin cancer	7.93e-06	0.000122	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TP53—skin cancer	7.9e-06	0.000122	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—HRAS—skin cancer	7.8e-06	0.00012	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—HRAS—skin cancer	7.76e-06	0.00012	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL6—skin cancer	7.74e-06	0.000119	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—HRAS—skin cancer	7.55e-06	0.000117	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL6—skin cancer	7.47e-06	0.000115	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL6—skin cancer	7.43e-06	0.000115	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL6—skin cancer	7.23e-06	0.000112	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—KRAS—skin cancer	7.22e-06	0.000111	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TP53—skin cancer	7.16e-06	0.000111	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TP53—skin cancer	7.05e-06	0.000109	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—HRAS—skin cancer	6.85e-06	0.000106	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—HRAS—skin cancer	6.74e-06	0.000104	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL6—skin cancer	6.56e-06	0.000101	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL6—skin cancer	6.45e-06	9.96e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TP53—skin cancer	6.41e-06	9.9e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—HRAS—skin cancer	6.13e-06	9.47e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL6—skin cancer	5.87e-06	9.06e-05	CbGpPWpGaD
